Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases

…, Z Řeháková, J Šinkora, J Hofman, P Drastich… - Immunology letters, 2004 - Elsevier
Commensal microflora (normal microflora, indigenous microbiota) consists of those micro-organisms,
which are present on body surfaces covered by epithelial cells and are exposed to …

The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of …

…, D Šrůtková, Z Zídek, M Schwarzer, P Drastich… - Cellular & molecular …, 2011 - nature.com
Metagenomic approaches are currently being used to decipher the genome of the microbiota
(microbiome), and, in parallel, functional studies are being performed to analyze the effects …

[HTML][HTML] Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis

…, J Brezina, P Wohl, J Spicak, P Drastich - World journal of …, 2017 - ncbi.nlm.nih.gov
AIM To characterize the gut bacterial microbiota of patients with primary sclerosing cholangitis
(PSC) and ulcerative colitis (UC). METHODS Stool samples were collected and relevant …

Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in …

L Frolova, P Drastich, P Rossmann… - … of Histochemistry & …, 2008 - journals.sagepub.com
Dysregulation of innate and adaptive intestinal immune responses to bacterial microbiota is
supposed to be involved in pathogenetic mechanisms of inflammatory bowel diseases (IBDs)…

Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis

M Lukas, P Drastich, M Konecny… - Inflammatory bowel …, 2010 - academic.oup.com
Background Increased activity of intestinal alkaline phosphatase (AP) occurs locally in patients
with ulcerative colitis (UC), aimed at repairing inflammatory tissue damage. We evaluated …

Endoscopic treatment of malignant gastric and duodenal strictures: a prospective, multicenter study

…, MJ Bourke, SJ Williams, J Spicak, P Drastich… - Gastrointestinal …, 2014 - Elsevier
… Williams MD, MBBS, FRACP 4 , Julius Spicak MD, PhD 5 , Pavel Drastich MD, PhD 5 ,
Massimiliano Mutignani MD 1 , Vincenzo Perri MD 1 , André Roy MD, LMCC, CSPQ, FRCSC 6 , …

A Current State of Proteomics in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Search and Review

O Fabian, L Bajer, P Drastich, K Harant… - International Journal of …, 2023 - mdpi.com
Inflammatory bowel diseases (IBD) are systemic immune-mediated conditions with predilection
for the gastrointestinal tract and include Crohn’s disease and ulcerative colitis. Despite …

Gut microbiome changes in patients with active left-sided ulcerative colitis after fecal microbiome transplantation and topical 5-aminosalicylic acid therapy

…, KO Fliegerová, S Kvasnová, L Bajer, P Drastich - Cells, 2020 - mdpi.com
Ulcerative colitis (UC) is an inflammatory bowel disease, and intestinal bacteria are implicated
in the pathogenesis of this disorder. The administration of aminosalicylates (5-ASA) is a …

Fecal microbial transplantation versus mesalamine enema for treatment of active left-sided ulcerative colitis—Results of a randomized controlled trial

…, M Chahrazed, J Mareš, J Špičák, P Drastich - Journal of clinical …, 2021 - mdpi.com
Background and Aims: Ulcerative colitis (UC) is a chronic inflammatory disease. Fecal
microbial transplantation (FMT) is a promising alternative treatment. Methods: This multicenter, …

Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis

…, Z Zádorová, J Hajer, P Drastich… - Scandinavian journal …, 2016 - Taylor & Francis
Objective: The infliximab biosimilar CT-P13 (Remsima ® , Inflectra ® ) was approved in Europe
for the treatment of inflammatory bowel disease (IBD) based on extrapolation of data from …